Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

40.16
+0.41001.03%
Pre-market: 39.65-0.5100-1.27%08:57 EDT
Volume:1.41M
Turnover:57.16M
Market Cap:2.87B
PE:-8.61
High:41.55
Open:40.38
Low:39.83
Close:39.75
52wk High:56.05
52wk Low:18.53
Shares:71.36M
Float Shares:50.20M
Volume Ratio:0.82
T/O Rate:2.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6644
EPS(LYR):-4.6644
ROE:-50.71%
ROA:-28.36%
PB:4.74
PE(LYR):-8.61

Loading ...

Vera Therapeutics Announces Pricing of Public Offering of Class a Common Stock

THOMSON REUTERS
·
Dec 10, 2025

Vera Therapeutics Plans Offering of Common Shares

MT Newswires Live
·
Dec 09, 2025

Vera Therapeutics Inc - Plans $200 Mln Public Offering of Class a Stock

THOMSON REUTERS
·
Dec 09, 2025

Press Release: Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Dow Jones
·
Dec 09, 2025

Vera Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Dec 08, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 06, 2025

Vera Therapeutics Chief Regulatory Officer William D. Turner Reports Sale of Common Shares

Reuters
·
Dec 05, 2025

Vera Therapeutics Inc : JP Morgan Raises Target Price to $99 From $52

THOMSON REUTERS
·
Dec 03, 2025

Will Vera Therapeutics (VERA) Strengthen Its Commercial Edge With Board Appointment of James R. Meyers?

Simply Wall St.
·
Dec 01, 2025

A Fresh Look at Vera Therapeutics (VERA) Valuation as Analyst Optimism Follows Board Addition and FDA Milestone

Simply Wall St.
·
Nov 29, 2025

Vera Therapeutics Appoints James R. Meyers to Board of Directors

Reuters
·
Nov 27, 2025

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to Its Board of Directors

THOMSON REUTERS
·
Nov 27, 2025

Optimistic Buy Rating for Vera Therapeutics Driven by Atacicept’s Commercial Potential and Favorable Valuation

TIPRANKS
·
Nov 26, 2025

Wells Fargo Keeps Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Nov 26, 2025

Buy Recommendation for Vera Therapeutics: Atacicept’s Market Potential and Efficacy Drive Positive Outlook

TIPRANKS
·
Nov 26, 2025

Vera Therapeutics Executive Makes a Noteworthy Stock Sale

TIPRANKS
·
Nov 26, 2025

Vera Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire
·
Nov 24, 2025

Vera Therapeutics Q3 EPS USD -1.26 Vs. IBES Estimate USD -1.17

Reuters
·
Nov 20, 2025

Vera Therapeutics (VERA): Valuation Insights Following Positive Phase 3 Data, FDA Filing, and Yale Investment

Simply Wall St.
·
Nov 16, 2025

Vera Therapeutics (VERA) Is Up 12.5% After Atacicept BLA Filing and Positive Phase 3 Data

Simply Wall St.
·
Nov 15, 2025